Principal Financial Group Inc. Has $22.17 Million Stock Holdings in Insulet Corporation (NASDAQ:PODD)

Principal Financial Group Inc. reduced its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 1.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 84,438 shares of the medical instruments supplier's stock after selling 1,527 shares during the quarter. Principal Financial Group Inc. owned about 0.12% of Insulet worth $22,174,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter valued at about $36,000. Itau Unibanco Holding S.A. bought a new stake in shares of Insulet in the 4th quarter valued at about $42,000. Golden State Wealth Management LLC increased its stake in shares of Insulet by 553.1% in the 1st quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock valued at $55,000 after acquiring an additional 177 shares during the last quarter. Assetmark Inc. increased its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after acquiring an additional 246 shares during the last quarter. Finally, Coppell Advisory Solutions LLC increased its stake in shares of Insulet by 135.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock valued at $74,000 after acquiring an additional 162 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PODD. The Goldman Sachs Group began coverage on Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 price target for the company. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Raymond James Financial reaffirmed an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Citigroup reiterated a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Finally, Barclays increased their target price on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and a consensus target price of $321.00.

Insulet Stock Down 2.7%

NASDAQ:PODD traded down $8.08 during trading hours on Friday, reaching $289.32. 507,503 shares of the stock were exchanged, compared to its average volume of 721,324. Insulet Corporation has a twelve month low of $173.00 and a twelve month high of $329.33. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. The firm has a 50 day moving average of $307.29 and a 200 day moving average of $280.15. The stock has a market cap of $20.36 billion, a PE ratio of 52.04, a PEG ratio of 2.58 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.73 EPS. On average, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president owned 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.